Promis Neurosciences (NASDAQ:PMN – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
Valuation and Earnings
This table compares Promis Neurosciences and Beam Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Promis Neurosciences | N/A | N/A | $2.78 million | ($0.21) | -2.05 |
| Beam Therapeutics | $63.52 million | 33.25 | -$376.74 million | ($4.50) | -4.64 |
Insider and Institutional Ownership
50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 6.1% of Promis Neurosciences shares are held by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Promis Neurosciences and Beam Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Promis Neurosciences | 0 | 0 | 3 | 0 | 3.00 |
| Beam Therapeutics | 0 | 2 | 9 | 3 | 3.07 |
Promis Neurosciences currently has a consensus target price of $4.33, suggesting a potential upside of 907.75%. Beam Therapeutics has a consensus target price of $48.45, suggesting a potential upside of 132.06%. Given Promis Neurosciences’ higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than Beam Therapeutics.
Risk & Volatility
Promis Neurosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.
Profitability
This table compares Promis Neurosciences and Beam Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Promis Neurosciences | N/A | -266.69% | -131.59% |
| Beam Therapeutics | -661.31% | -43.15% | -31.06% |
Summary
Beam Therapeutics beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.
About Promis Neurosciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
